{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:40:26Z","timestamp":1765546826870,"version":"3.41.2"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T00:00:00Z","timestamp":1640044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81700140, 81873449, 81900130, 81970136, 81970142, 82000132, 82000158"],"award-info":[{"award-number":["81700140, 81873449, 81900130, 81970136, 81970142, 82000132, 82000158"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Several clinical trials have shown promising efficacy of pegylated interferon (Peg-IFN) in the first- and second-line polycythemia vera (PV) and essential thrombocythemia (ET). However, the efficacy and safety of Peg-IFN in the real world have rarely been reported. Hence, we conducted a prospective, single-center, single-arm, open exploratory study, which aimed to explore the hematologic response, molecular response, safety, and tolerability of patients with PV and ET treated with Peg-IFN in the real world. This study included newly diagnosed or previously treated patients with PV and ET, aged 18 years or older, admitted to the Department of Hematology of the First Affiliated Hospital of Soochow University from November 2017 to October 2019. The results revealed that complete hematological response (CHR) was achieved in 66.7% of patients with PV and 76.2% of patients with ET, and the molecular response was obtained in 38.5% of patients with PV and 50% of patients with ET after 48 weeks of Peg-IFN treatment. Peg-IFN is safe, effective and well tolerated in most patients. In the entire cohort, 4 patients (9.1%) discontinued treatment due to drug-related toxicity. In conclusion, Peg-IFN is a promising strategy in myeloproliferative neoplasms (MPNs), and Peg-IFN alone or in combination with other drugs should be further explored to reduce treatment-related toxicity and improve tolerability.<\/jats:p>","DOI":"10.3389\/fonc.2021.797825","type":"journal-article","created":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T04:54:06Z","timestamp":1640062446000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Pegylated Interferon Alpha-2b in Patients With Polycythemia Vera and Essential Thrombocythemia in the Real World"],"prefix":"10.3389","volume":"11","author":[{"given":"Yingxin","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifeng","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiannong","family":"Cen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingqing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinlan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Depei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suning","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1406186","article-title":"Myeloproliferative Neoplasms","volume":"376","author":"Spivak","year":"2017","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2015.05.014","article-title":"Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice","volume":"90","author":"Tefferi","year":"2015","journal-title":"Mayo Clinic Proc"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.6474","article-title":"Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F","volume":"33","author":"Stein","year":"2015","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-695940","article-title":"Genetic Basis and Molecular Pathophysiology of Classical Myeloproliferative Neoplasms","volume":"129","author":"Vainchenker","year":"2017","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00281-018-0700-2","article-title":"Perspectives on Interferon-Alpha in the Treatment of Polycythemia Vera and Related Myeloproliferative Neoplasms: Minimal Residual Disease and Cure","volume":"41","author":"Hasselbalch","year":"2019","journal-title":"Semin Immunopathol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-387787","article-title":"Assessment and Prognostic Value of the European LeukemiaNet Criteria for Clinicohematologic Response, Resistance, and Intolerance to Hydroxyurea in Polycythemia Vera","volume":"119","author":"Alvarez-Larr\u00e1n","year":"2012","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1998.tb01039.x","article-title":"Long-Term Therapeutic Efficacy and Toxicity of Recombinant Interferon-Alpha 2a in Polycythaemia Vera","volume":"60","author":"Foa","year":"1998","journal-title":"Eur J Haematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830480112","article-title":"Role of Interferon Alpha-2a in the Treatment of Polycythemia Vera","volume":"48","author":"Foa","year":"1995","journal-title":"Am J Hematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.6075","article-title":"Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera","volume":"27","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23928","article-title":"Molecular Responses and Chromosomal Aberrations in Patients With Polycythemia Vera Treated With Peg-Proline-Interferon Alpha-2b","volume":"90","author":"Them","year":"2015","journal-title":"Am J Hematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.06.012","article-title":"Long Term Molecular Responses in a Cohort of Danish Patients With Essential Thrombocythemia, Polycythemia Vera and Myelofibrosis Treated With Recombinant Interferon Alpha","volume":"37","author":"Stauffer Larsen","year":"2013","journal-title":"Leukemia Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-143537","article-title":"Pegylated Interferon-Alfa-2a Induces Complete Hematologic and Molecular Responses With Low Toxicity in Polycythemia Vera","volume":"112","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41408-018-0133-0","article-title":"Ropeginterferon Alpha-2b Targets JAK2V617F-Positive Polycythemia Vera Cells In Vitro and In Vivo","volume":"8","author":"Verger","year":"2018","journal-title":"Blood Cancer J"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199710)56:2<126::AID-AJH10>3.0.CO;2-A","article-title":"Polycythemia Vera Treated With Recombinant Interferon-Alpha 2a: Evidence of a Selective Effect on the Malignant Clone","volume":"56","author":"Massaro","year":"1997","journal-title":"Am J Hematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30030-3","article-title":"Pegylated Interferon Alfa-2a in Patients With Essential Thrombocythaemia or Polycythaemia Vera: A Post-Hoc, Median 83 Month Follow-Up of an Open-Label, Phase 2 Trial","volume":"4","author":"Masarova","year":"2017","journal-title":"Lancet Haematol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/10245332.2015.1111644","article-title":"Optimal Therapy for Polycythemia Vera and Essential Thrombocythemia: Preferred Use of Interferon Therapy Based on Phase 2 Trials","volume":"21","author":"Silver","year":"2016","journal-title":"Hematology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-04-637280","article-title":"Ropeginterferon Alfa-2b, a Novel Ifn\u03b1-2b, Induces High Response Rates With Low Toxicity in Patients With Polycythemia Vera","volume":"126","author":"Gisslinger","year":"2015","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000428","article-title":"Pegylated Interferon Alfa-2a for Polycythemia Vera or Essential Thrombocythemia Resistant or Intolerant to Hydroxyurea","volume":"134","author":"Yacoub","year":"2019","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30236-4","article-title":"Ropeginterferon Alfa-2b Versus Standard Therapy for Polycythaemia Vera (PROUD-PV and CONTINUATION-PV): A Randomised, non-Inferiority, Phase 3 Trial and its Extension Study","volume":"7","author":"Gisslinger","year":"2020","journal-title":"Lancet Haematol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.326","article-title":"Interferon-Alpha for the Therapy of Myeloproliferative Neoplasms: Targeting the Malignant Clone","volume":"30","author":"Kiladjian","year":"2016","journal-title":"Leukemia"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO Classification of Lymphoid Neoplasms and Beyond: Evolving Concepts and Practical Applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-09-176818","article-title":"Response Criteria for Essential Thrombocythemia and Polycythemia Vera: Result of a European LeukemiaNet Consensus Conference","volume":"113","author":"Barosi","year":"2009","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2017.0157","article-title":"NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018","volume":"15","author":"Mesa","year":"2017","journal-title":"J Natl Compr Cancer Netw"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040992","article-title":"Interferon Alpha Therapy Increases Pro-Thrombotic Biomarkers in Patients With Myeloproliferative Neoplasms","volume":"12","author":"Faille","year":"2020","journal-title":"Cancers"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2020.08.021","article-title":"Real-World Experience With Ropeginterferon-Alpha 2b (Besremi) in Philadelphia-Negative Myeloproliferative Neoplasms","volume":"120","author":"Huang","year":"2021","journal-title":"J Formosan Med Assoc"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30373-2","article-title":"Ropeginterferon Alfa-2b Versus Phlebotomy in Low-Risk Patients With Polycythaemia Vera (Low-PV Study): A Multicentre, Randomised Phase 2 Trial","volume":"8","author":"Barbui","year":"2021","journal-title":"Lancet Haematol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-785790","article-title":"Ruxolitinib vs Best Available Therapy for ET Intolerant or Resistant to Hydroxycarbamide","volume":"130","author":"Harrison","year":"2017","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0638-y","article-title":"Distinct Effects of Ruxolitinib and Interferon-Alpha on Murine JAK2V617F Myeloproliferative Neoplasm Hematopoietic Stem Cell Populations","volume":"34","author":"Austin","year":"2020","journal-title":"Leukemia"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1619","article-title":"Safety and Efficacy of Combination Therapy of Interferon-\u03b12 and Ruxolitinib in Polycythemia Vera and Myelofibrosis","volume":"7","author":"Mikkelsen","year":"2018","journal-title":"Cancer Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-784942","article-title":"Ruxolitinib-Induced Defects in DNA Repair Cause Sensitivity to PARP Inhibitors in Myeloproliferative Neoplasms","volume":"130","author":"Nieborowska-Skorska","year":"2017","journal-title":"Blood"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.797825\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T04:54:10Z","timestamp":1640062450000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.797825\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,21]]},"references-count":30,"alternative-id":["10.3389\/fonc.2021.797825"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.797825","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2021,12,21]]},"article-number":"797825"}}